Study of QL2109 in healthy men
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new biosimilar drug called QL2109, which is similar to daratumumab (a treatment for multiple myeloma). Healthy men aged 18-50 will receive one dose to see how the body processes it and if it causes any side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man between 18 and 50 years old.
- You weigh at least 55 kilograms (about 121 pounds).
- You have not used daratumumab, any CD38-targeting drug, or other monoclonal antibodies in the last 6 months.
- You do not have serious health problems (like heart, lung, immune, or blood disorders).
- You are willing to use reliable birth control for yourself and your partner during the study and for 6 months after.
- You have not donated blood or had major surgery in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, QL2109, against an approved drug, Darzalex Faspro, for people with multiple myeloma that has worsened after prior treatments. It aims to see if QL2109 works as well or better.
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
This trial tests a new injectable drug, TQB2029, for people with multiple myeloma. It aims to see if the drug is safe and effective, and may be an option if you have measurable disease and are in relatively good health.
This study tests a new drug called TQB2934 for patients whose multiple myeloma (a blood cancer) has returned or stopped responding to previous treatments. The goal is to see if this injection can help control the disease.
This trial tests a new drug, BL-M24D1, for people with multiple myeloma or other blood cancers that have come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug (JNJ-79635322) combined with other treatments like daratumumab or pomalidomide for people with multiple myeloma. It aims to see if these combinations are safe and effective for newly diagnosed or previously treated patients.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.